7 (2), e1891
I waited only five minutes to be seen
In summary, any weight loss benefits are minimal, depend more on maintaining healthy habits, and arent significant enough to justify the cost or potential risks for most people
One report found that people with diabetes who took GLP-1 agonists were less likely to be diagnosed with depression or anxiety later however, this is observational research, which cant prove cause and effect
Discussion In this phase 2, randomized, double-blind, placebo-controlled trial of orforglipron, participants in all dose cohorts (12, 24, 36, and 45 mg) had a greater decrease from baseline in body weight than those in the placebo group, both at 26 weeks (primary end point) and at 36 weeks (secondary end point)